Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05923905
PHASE4

Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients

Sponsor: Peking University Third Hospital

View on ClinicalTrials.gov

Summary

This is a randomized double-blind controlled exploratory clinical study to evaluate the efficacy and safety of FB1006 in the treatment of amyotrophic lateral sclerosis (ALS) patients.

Official title: Randomized Double-blind Controlled Exploratory Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

64

Start Date

2023-01-18

Completion Date

2027-09-30

Last Updated

2023-11-22

Healthy Volunteers

No

Interventions

DRUG

FB1006

30mg/day

DRUG

Placebo

30mg/day

Locations (1)

Peking University Third Hospital

Beijing, Beijing Municipality, China